E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Psychotic major depression (major depressive episode, severe, with psychotic features) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037250 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To measure safety and tolerability of re-exposure to 2 weeks of adjunctive therapy with Org 34517 during treatment and up to 2 weeks after discontinuation in subjects with psychotic depression on ‘usual treatment’, who were recently treated with 900 mg Org 34517 in trial 28130 (prospective, double-blind, randomized, placebo-controlled dose finding study of the efficacy and safety of 2 target doses of Org 34517 used as adjunctive therapy in subjects with psychotic depression). |
|
E.2.2 | Secondary objectives of the trial |
To measure safety and tolerability of re-exposure to 2 weeks of adjunctive therapy with Org 34517 during treatment and up to 2 weeks after discontinuation in subjects with psychotic depression on ‘usual treatment’, who were recently treated with 300 mg Org 34517 in trial 28130. To study efficacy of re-exposure to 2 weeks of adjunctive therapy with Org 34517 in subjects with psychotic depression on ‘usual treatment’, who were recently treated with 900 mg Org 34517 in trial 28130. To study efficacy of re-exposure to 2 weeks of adjunctive therapy with Org 34517 in subjects with psychotic depression on ‘usual treatment’, who were recently treated with 300 mg Org 34517 in trial 28130. To study the maintenance of treatment effect of a re-exposure of 2 weeks of adjunctive therapy with Org 34517 in subjects with psychotic depression on ‘usual treatment’ up to 2 weeks after the discontinuation of adjunctive treatment, who were recently treated with 300 or 900 mg Org 34517 in trial 28130. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
a) provide voluntary written informed consent for trial participation after the scope and nature of the investigation have been explained to them, and before starting any trial-related activities; b) have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of trial 28130; c) have a CGI of Severity score of 3 or greater at Day 43 of trial 28130 and at Day 1 of trial 28133, or a lower score when the investigator is of the opinion that further resolution of symptoms is warranted; and d) be on a stable dose of ‘usual treatment’, which must consist of an antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes. |
|
E.4 | Principal exclusion criteria |
a) have experienced any of the following significant safety outcomes in trial 28130: 1. Severe breakthrough bleeding; 2. Diagnosis of prostatitis; 3. Abnormal level of testosterone at Day 15 of trial 28130; 4. A significant increase in suicidality at any time point as evidenced by an ISST score > 9 or an increase of 3 points or more post-randomisation; 5. A doubling of trial 28130 screening values in two or more tests of hepatic function (ASAT, ALAT, bilirubin, alkaline phosphatase or gamma GT); 6. Emergent dermatological condition or worsening of a pre-existing dermatological condition; 7. A clinically significant abnormal ECG, as judged by the QECG cardiologist; 8. For male subjects: Obstructive urinary symptoms; 9. Any adverse event deemed relevant for exclusion in trial 28133 by the investigator. b) have an abnormal PSA test at Day -7 of trial 28133 c) are at significant risk of committing suicide, as indicated by a score greater than 9 on the revised ISST at Day -7 or Day 1; d) are currently treated with carbamazepine or valproate; e) are currently treated with midazolam; f) are currently treated with clozapine; g) have been treated with electroconvulsive therapy (ECT) in the current episode; h) are currently treated with more than one antidepressant; i) are currently treated with more than one antipsychotic; j) are currently treated with more than one mood stabilizer; k) have ‘usual treatment’ started or discontinued in the 2 weeks before Day 1; l) have a ‘usual treatment’ dose change within one week prior to Day 1; m) have any clinically unstable or uncontrollable renal, hepatic, respiratory, hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy; n) have known hypersensitivity reactions to glucocorticoid antagonists; o) have any clinically significant abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or ECG results, or a clinically significant abnormal outcome at the physical examination at Day -7; p) have a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Day -7; q) have any untreated or uncompensated clinically significant endocrine disorder; r) are using hormone replacement therapy at Day -7; s) require concomitant treatment with corticosteroids, like dexamethasone, prednisone or cortisol (topical use is allowed); t) are women of childbearing potential without adequate contraception (an IUD, oral contraceptives in combination with a barrier method or a condom combined with spermicide, are considered adequate); or u) are women with a positive pregnancy test at Day -7 or 1, or are breast feeding mothers; v) are currently treated with systemic or topical ketaconazole. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability of re-exposure to 2 weeks of adjunctive therapy with Org 34517 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 5 |